Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.
Samer K KhaledKathleen J ClaesYeow Tee GohYok Lam KwongNelson R LeungWłodzimierz MendrekRyotaro NakamuraJameela SatharEdmund NgNarinder NangiaSteve WhitakerAlessandro Rambaldinull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
In this study, narsoplimab treatment was safe, significantly improved laboratory TMA markers, and resulted in clinical response and favorable overall survival.